VISTA in hematological malignancies: a review of the literature
In recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1466839/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119281888067584 |
|---|---|
| author | Yuanjia Duan Yuanjia Duan Yuanjia Duan Xiaotong Ren Xiaotong Ren Xiaotong Ren Xinyu Guo Xinyu Guo Xinyu Guo Jiayi Xie Jiayi Xie Jiayi Xie Zhaoyun Liu Zhaoyun Liu Zhaoyun Liu Lijuan Li Lijuan Li Lijuan Li |
| author_facet | Yuanjia Duan Yuanjia Duan Yuanjia Duan Xiaotong Ren Xiaotong Ren Xiaotong Ren Xinyu Guo Xinyu Guo Xinyu Guo Jiayi Xie Jiayi Xie Jiayi Xie Zhaoyun Liu Zhaoyun Liu Zhaoyun Liu Lijuan Li Lijuan Li Lijuan Li |
| author_sort | Yuanjia Duan |
| collection | DOAJ |
| description | In recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor of T-cell activation (VISTA) is a new type of immune checkpoint receptor that is highly expressed in various tumors. It is co-expressed with PD-1, T-cell immunoglobulin domain, mucin domain-3 (Tim-3), T-cell immunoglobulin, and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and is associated with prognosis, which suggests that it may be a target for immunotherapy. As an immune checkpoint receptor with no mature drugs, VISTA is highly expressed in acute myeloid leukemia (AML), multiple myeloma (MM), and other hematological malignancies; however, its pathogenic mechanism should be defined to better guide treatment. |
| format | Article |
| id | doaj-art-a5e4ce537ab94a77a259d9e17493c9d1 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a5e4ce537ab94a77a259d9e17493c9d12024-12-17T06:23:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14668391466839VISTA in hematological malignancies: a review of the literatureYuanjia Duan0Yuanjia Duan1Yuanjia Duan2Xiaotong Ren3Xiaotong Ren4Xiaotong Ren5Xinyu Guo6Xinyu Guo7Xinyu Guo8Jiayi Xie9Jiayi Xie10Jiayi Xie11Zhaoyun Liu12Zhaoyun Liu13Zhaoyun Liu14Lijuan Li15Lijuan Li16Lijuan Li17Department of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaTianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, ChinaTianjin Institute of Hematology, Tianjin, ChinaIn recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor of T-cell activation (VISTA) is a new type of immune checkpoint receptor that is highly expressed in various tumors. It is co-expressed with PD-1, T-cell immunoglobulin domain, mucin domain-3 (Tim-3), T-cell immunoglobulin, and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and is associated with prognosis, which suggests that it may be a target for immunotherapy. As an immune checkpoint receptor with no mature drugs, VISTA is highly expressed in acute myeloid leukemia (AML), multiple myeloma (MM), and other hematological malignancies; however, its pathogenic mechanism should be defined to better guide treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1466839/fullimmune checkpoint receptorsVISTAhematological malignanciestumor microenvironmentimmunotherapy |
| spellingShingle | Yuanjia Duan Yuanjia Duan Yuanjia Duan Xiaotong Ren Xiaotong Ren Xiaotong Ren Xinyu Guo Xinyu Guo Xinyu Guo Jiayi Xie Jiayi Xie Jiayi Xie Zhaoyun Liu Zhaoyun Liu Zhaoyun Liu Lijuan Li Lijuan Li Lijuan Li VISTA in hematological malignancies: a review of the literature Frontiers in Immunology immune checkpoint receptors VISTA hematological malignancies tumor microenvironment immunotherapy |
| title | VISTA in hematological malignancies: a review of the literature |
| title_full | VISTA in hematological malignancies: a review of the literature |
| title_fullStr | VISTA in hematological malignancies: a review of the literature |
| title_full_unstemmed | VISTA in hematological malignancies: a review of the literature |
| title_short | VISTA in hematological malignancies: a review of the literature |
| title_sort | vista in hematological malignancies a review of the literature |
| topic | immune checkpoint receptors VISTA hematological malignancies tumor microenvironment immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1466839/full |
| work_keys_str_mv | AT yuanjiaduan vistainhematologicalmalignanciesareviewoftheliterature AT yuanjiaduan vistainhematologicalmalignanciesareviewoftheliterature AT yuanjiaduan vistainhematologicalmalignanciesareviewoftheliterature AT xiaotongren vistainhematologicalmalignanciesareviewoftheliterature AT xiaotongren vistainhematologicalmalignanciesareviewoftheliterature AT xiaotongren vistainhematologicalmalignanciesareviewoftheliterature AT xinyuguo vistainhematologicalmalignanciesareviewoftheliterature AT xinyuguo vistainhematologicalmalignanciesareviewoftheliterature AT xinyuguo vistainhematologicalmalignanciesareviewoftheliterature AT jiayixie vistainhematologicalmalignanciesareviewoftheliterature AT jiayixie vistainhematologicalmalignanciesareviewoftheliterature AT jiayixie vistainhematologicalmalignanciesareviewoftheliterature AT zhaoyunliu vistainhematologicalmalignanciesareviewoftheliterature AT zhaoyunliu vistainhematologicalmalignanciesareviewoftheliterature AT zhaoyunliu vistainhematologicalmalignanciesareviewoftheliterature AT lijuanli vistainhematologicalmalignanciesareviewoftheliterature AT lijuanli vistainhematologicalmalignanciesareviewoftheliterature AT lijuanli vistainhematologicalmalignanciesareviewoftheliterature |